On Dec. 4, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Bizengri (zenocutuzumab-zbco) for people with metastatic non-small cell lung cancer (NSCLC) who have an NRG1 mutation following progression on or after prior systemic therapy. [...]
On December 4, 2024, the U.S. Food and Drug Administration (FDA) approved the use of Imfinzi (durvalumab) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease did not progress following combination platinum-based chemotherapy and radiation. Previously approved [...]
Matthew Reiss MSE PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer, and Jared Weiss MD, Section Chief of Thoracic and Head & Neck Oncology, Professor of Medicine, University of North Carolina at Chapel Hill It [...]
By Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation; Andrew Ciupek, PhD, Associate Director, Clinical Research; Shanada Monestime, PharmD, BCOP, Director, Community Engaged Research; Heather Law, MA, Associate Director, Lung Cancer Registry; Richard Erwin, Executive Director of the [...]
By Renee Botello MSc, Treatment and Trials Navigator A lung cancer diagnosis can be overwhelming and is life-changing for patients and caregivers. Navigating it is challenging without the correct information. The internet has become many people's primary [...]
Recently, lung cancer professionals from across the globe gathered to connect and discuss developments impacting the lung cancer community at the International Association for the Study of Lung Cancer (IASLC)’s World Conference for Lung Cancer (WCLC) in San Diego, [...]
On October 15, 2024, the U.S. Food and Drug Administration (FDA) approved the use of a wearable treatment device, Optune Lua, in combination with PD-1/PD-L1 immunotherapies or the chemotherapy docetaxel for people with metastatic non-small cell lung cancer (NSCLC) [...]
On October 15, 2024, the U.S. Food and Drug Administration (FDA) approved the use of a wearable treatment device, Optune Lua, in combination with PD-1/PD-L1 immunotherapies or the chemotherapy docetaxel for people with metastatic non-small cell lung cancer (NSCLC) who [...]
On October 3, 2024, the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) to be used with platinum-doublet chemotherapy as a treatment before surgery, followed by Opdivo (nivolumab) alone after surgery. This approval is for people with resectable (removable [...]
On September 25, 2024, the U.S. Food and Drug Administration (FDA) approved Tagrisso (osimertinib) for people with unresectable stage 3 (III) non-small cell lung cancer (NSCLC). It’s approved for people who have both: Disease that has not progressed during [...]